The CDTI SICC Innvierte of investing in Innovation, along with Nanoligent INVEREADY BIOTECH IV PARALLEL, SCR, S.A. and INVEREADY BIOTECH IV, SCR S.A., in order to develop an oncological nanofármaco

Nanoligent biotechnology is developing therapies against the cancer using proteins organized in nanoparticles and lymphocyte coupled with drugs.

The main objective of this company, led by Dr. Montserrat Cano and dr. Manuel Rodríguez Mariscal, is to develop new medicines anticancerosos directed toward aggressive tumours using a pioneering technology platform based on nanoconjugados of protein and drugs.

These nanoparticles proteína-fármaco are capable of acting in an accurate cancer cells, ensuring that the drug reaches its destination. In this way, through the use of specific ligands, the drug is released Only on your site. Unlike the traditional therapies, the architecture of Nanoligent proteica remains highly stable after administration on the agency, avoiding drug action during its systemic circulation and to focus its action in specific sites. In Addition, the sequence peptídica of human origin prevents unwanted immune responses, which further improves the safety and effectiveness of Nanoligent treatments.

This innovative approach is key to the medicine in oncology, precisely because it offers a high rate of treatment and minimizes the side effects.

The commitment of this company was founded as spin-off the Universitat autònoma de Barcelona (UAB) and the Institut de Recerca's ward of the Santa Creu i Sant Pau, is to reduce systemic toxicity and, at the same time, improve the effectiveness of treatment.

The CDTI Innovation, through Innvierte, has closed an operation of investment in this endeavour with INVEREADY BIOTECH IV PARALLEL, SCR, S.A. and INVEREADY BIOTECH IV, SCR S.A., with an amount of investment of €3.6 million. This participation, the CDTI Innovation contributes to the development of the technology platform precision nanoterapia for the advancement of new medicines anticancerosos, safer and more effective, that improve the lives of patients.

Inveready

INVEREADY ASSET MANAGEMENT, S.G.E.I.C., S.A. is a leader in financial services specialized in alternative asset management, and of traditional investment funds, including INVEREADY BIOTECH IV PARALLEL, SCR, S.A. and INVEREADY BIOTECH IV, SCR S.A., Founded in 2008, as an investment fund venture Inveready has evolved into one of the most active investment in the field of small and medium-sized enterprises in Spain currently managed over 2.2bn €.

The financial group organizes its services in three principal lines of business: ‘ Alternative Assets ’, which brings together different strategies of direct investment (Venture Capital, Life Science Venture Debt, Strategic Public Equity, Private Equity and A), ‘ ’ s Wealth Management advice to clients in different products and value-added services and ‘ ’ Investment funds that invest in small capitalization values with a value investing through management of the True Value.

With 60 employees, Inveready is based in San sebastian, and has offices in Barcelona and Madrid. It has been recognized as' best venture capital firm ’ in 2017 by SpainCap as' best debt fund of risk to europe ’ in 2023 by Preqin, among others.

Innvierte

Innvierte is an initiative aimed at promoting the entrepreneurial innovation through support to the risk capital investment in technology-based enterprises or innovative programme. This is done through the collective investment type closed Innvierte Sustainable Economy SICC S.M.E., S.A., self-managed and under the supervision of the national Values and that the CDTI Innovation is a shareholder Only.

To date, the CDTI innovation has committed 2.847 M €in 63 investment vehicles that have invested in more than 632 companies, and through its joint investment line directly committed an amount of 726 M €in 191 companies.

Innvierte fits into the strategy for science, technology and innovation 2021-2027, adopted by decision of the council of ministers, in september. This 2020 Strategy contains goals, the reforms and measures to be taken throughout the area of r + D + i in order to boost their growth and impact, and is one of the pillars on which the design of the government's policy in r + D + i for the coming years.

CDTI Innovation

The centre for technological development and innovation, CDTI E.P.E. is the agency for innovation of the ministry of science, innovation and universities, whose goal is the promotion of technological innovation in business. The CDTI mission is to ensure that the business fabric english generates and transform knowledge into growth científico-técnico globally competitive, sustainable and inclusive. By 2024, within the framework of a new strategic plan, the CDTI provided more than $2.3 billion euros of support for business startups and spain.

Further information,

Office of the press
prensa@cdti.es
91-581.55.00

On The Internet
Website:www.cdti.es
In Linkedin:https :// www.linkedin.com/company/29815
X:https :// twitter.com/CDTI _ innovation
On Youtube:https :// www.youtube.com/user/CDTIoficial

Nanoligent:
Website:https :// www.nanoligent.com/
In LinkedIn:https :// www.linkedin.com/company/nanoligent/

Inveready:
Website:https :// inveready.com/
In LinkedIn:https :// www.linkedin.com/company/inveready/
X:https :// x.com/inveready

This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (@CDTI _ innovation).